Eleclazine + Eleclazine placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Long QT Syndrome Type 3
Conditions
Long QT Syndrome Type 3
Trial Timeline
Dec 17, 2014 → Feb 15, 2017
NCT ID
NCT02300558About Eleclazine + Eleclazine placebo
Eleclazine + Eleclazine placebo is a phase 3 stage product being developed by Gilead Sciences for Long QT Syndrome Type 3. The current trial status is terminated. This product is registered under clinical trial identifier NCT02300558. Target conditions include Long QT Syndrome Type 3.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02300558 | Phase 3 | Terminated |
Competing Products
16 competing products in Long QT Syndrome Type 3
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ensitrelvir | Shionogi | Phase 2 | 52 |
| TBM100 | Novartis | Approved | 85 |
| GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Placebo + Ranolazine | Gilead Sciences | Phase 2 | 51 |
| GS-6615 | Gilead Sciences | Phase 1 | 32 |
| Nirmatrelvir + Ritonavir + Placebo | Pfizer | Phase 2 | 51 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) | ImmunityBio | Phase 2 | 49 |
| Anktiva | ImmunityBio | Phase 2 | 49 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |